Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (Nasdaq: OCUL) is an integrated biopharmaceutical company developing and commercializing ophthalmic therapies using its ELUTYX bioresorbable hydrogel technology. Its commercial product, DEXTENZA, is a corticosteroid insert approved in the United States to treat ocular inflammation and pain… From the company’s description.
Over the twelve months to Jun 30, 2026, Ocular Therapeutix, Inc. reported revenue of $52.05M, down 8.1% from a year earlier, and a net loss of $301.45M. Its operating margin was −603.0%, and operations used $238.24M in cash. In fiscal 2025, it reported revenue of $51.95M, down 18.5% from fiscal 2024, and a net loss of $265.94M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ocular Therapeutix, Inc. does
In the company’s own words
Ocular Therapeutix, Inc. (Nasdaq: OCUL) is an integrated biopharmaceutical company developing and commercializing ophthalmic therapies using its ELUTYX bioresorbable hydrogel technology. Its commercial product, DEXTENZA, is a corticosteroid insert approved in the United States to treat ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. The company’s lead investigational product, AXPAXLI, is an axitinib hydrogel delivered by intravitreal injection and is in Phase 3 development for wet age-related macular degeneration and diabetic retinal disease. Its other clinical-stage candidate, OTX-TIC, is a travoprost hydrogel studied for open-angle glaucoma and ocular hypertension. ELUTYX formulations are designed to provide local, programmed drug release before the hydrogel is absorbed. Ocular Therapeutix operates as one integrated business, with commercial activities for DEXTENZA and research and development focused on its product candidates. Its SOL-R Phase 3 trial for wet AMD had 631 subjects randomized as of 2025. Its website is www.ocutx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 1393434
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ocular Therapeutix, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ocular Therapeutix, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ocular Therapeutix, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ocular Therapeutix, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ocular Therapeutix, Inc.'s last four quarterly filings that the numbers alone won't show?”